GlobeNewsWire
09 Sept 2026, 23:25 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Disc Medicine reported positive initial Phase 2 results for DISC-3405 in patients with polycythemia vera (PV), showing reduced phlebotomy and controlled hematocrit. — Successful Phase 2 clinical data for a core pipeline asset significantly increases the probability of FDA approval and future commercial revenue.
+0.60The company plans to share FDA feedback from an end-of-phase 2 meeting and plans for pivotal development of selcodebart in anemia of myelofibrosis (MF) by the end of 2026. — Progressing a second asset toward pivotal trials reduces binary risk and expands the company's potential market reach in hematologic oncology.
+0.40Disc Medicine expects to provide initial data from the Phase 1b trial of DISC-3405 in sickle cell disease by the end of 2026. — Expansion into sickle cell disease provides additional long-term optionality, though early-phase data is less immediately impactful than Phase 2 results.
+0.20Continue reading
5 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company presented positive Phase 2 trial results for DISC-3405 and shared positive data for selcodebart.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
